Charlie Newton

Charlie Newton has served as a member of our Board of Directors since May 2022. Mr. Newton is the Chief Financial Officer of Lyell Immunopharma, a publicly traded biotechnology company. Prior to joining Lyell, he served as Managing Director & Co-Head of Healthcare Investment Banking in the Americas at BofA Securities, Managing Director & Co-Head of Healthcare Investment Banking in the Americas at Credit Suisse, and Managing Director & Head of Western Region Healthcare Investment Banking at Morgan Stanley. Mr. Newton advised on approximately $200 billion in mergers and acquisitions and raised nearly $60 billion in capital during his investment banking career. Mr. Newton currently serves as a board member at Novavax, Inc. and Keros Therapeutics, Inc. and previously served on the board of directors of 2seventy bio, Inc. until their acquisition by Bristol Myers Squibb, and Carmot Therapeutics, until their acquisition by Roche. Mr. Newton earned a M.B.A. from the Tuck School at Dartmouth College as well as a B.S. in Finance from Miami University.